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In genome-wide association studies (GWAS) of common genetic variants associated with circulating alpha-
and gamma-tocopherol concentrations in two adult cohorts comprising 5006 men of European descent, we
observed three loci associated with alpha-tocopherol levels, two novel single-nucleotide polymorphisms
(SNPs), rs2108622 on 19pter-p13.11 (P 5 1.7 3 10
28) and rs11057830 on 12q24.31 (P 5 2.0 3 10
28) and con-
ﬁrmed a previously reported locus marked by rs964184 on 11q23.3 (P 5 2.7 3 10
210). The three SNPs have
been reported to be associated with lipid metabolism and/or regulation. We replicated these ﬁndings in a
combined meta-analysis with two independent samples, P 5 7.8 3 10
212 (rs964184 on 11q23.3 near BUD13,
ZNF259 and APOA1/C3/A4/A5), P 5 1.4 3 10
210 (rs2108622 on 19pter-p13.11 near CYP4F2)a n dP 5 8.2 3
10
29 (rs11057830 on 12q24.31 near SCARB1). Combined, these SNPs explain 1.7% of the residual variance
in log alpha-tocopherol levels. In one of the two male GWAS cohorts (n 5 992), no SNPs were signiﬁcantly
associated with gamma-tocopherol concentrations after including data from the replication sample for 71
independent SNPs with P < 1 3 10
24 identiﬁed.
INTRODUCTION
Vitamin E has been examined for its possible role in pre-
venting chronic diseases including heart disease, diabetes
and cancer through its anti-oxidant and other properties
(1–7). It is an essential fat-soluble micronutrient encom-
passing four tocopherols and four tocotrienols that protect
the cellular membranes, low-density lipoprotein (LDL)
cholesterol and other molecules from oxidative damage.
Alpha-tocopherol, the primary vitamin E compound in
humans, also inhibits cell proliferation and angiogenesis
(8), induces apoptosis (9) and enhances immune function
(10).
A growing literature of novel genetic determinants of circu-
lating nutrients identiﬁed from genome-wide association
studies (GWAS) [e.g. vitamin B12 (11) and vitamin D (12)]
is enhancing our ability to investigate their associations with
human disease. With respect to vitamin E compounds, only
one GWAS of the circulating alpha-tocopherol phenotype
has been conducted, which found a single-nucleotide poly-
morphism (SNP) close to the apolipoprotein A5 (APOA5)
gene (rs12272004) to be associated with higher plasma
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Advance Access published on July 5, 2011alpha-tocopherol levels (13). The association between the
autosomal recessive neurodegenerative disease, AVED
(ataxia with isolated vitamin E deﬁciency) and mutations in
the gene, TTPA, on chromosome 8q13 encoding the alpha-
tocopherol transfer protein (14), has been established. We
report here ﬁndings from a GWAS meta-analysis of circulat-
ing alpha-tocopherol and gamma-tocopherol.
RESULTS
Alpha-tocopherol
In 4014 participants in the ATBC Study (Table 1), we found
evidence of novel quantitative trait loci for log-transformed
circulating alpha-tocopherol concentration. Figure 1 depicts
the Manhattan plot for genetic variants in relation to alpha-
tocopherol levels achieving genome-wide signiﬁcance on
11q23.3, 19pter-p13.11 and 12q24.31. In each region, there
are plausible candidate SNPs for follow-up: rs964184 near
BUD13 [(yeast) budding site selection protein 13], ZNF259
(zinc ﬁnger protein 259) and APOA1/C3/A4/A5 (apolipopro-
teins A1, C3, A4 and A5) on 11q23.3, rs2108622 in
CYP4F2 (cytochrome p450, family 4, subfamily F, polypep-
tide 2) on 19pter-p13.11 and rs11057830 in SCARB1 (scaven-
ger receptor class B member 1) 12p24.31 (Table 2). Our most
signiﬁcant ﬁndings were replicated in silico using two inde-
pendent data sets, with the combined meta-analysis revealing
markers below the threshold for genome-wide signiﬁcance,
namely, P ¼ 7.8 × 10
212 for rs964184, P ¼ 1.4 × 10
210 for
rs2108622 and P ¼ 8.2 × 10
29 for rs11057830.
Our GWAS identiﬁed an association between serum alpha-
tocopherol and rs964184 on chromosome 11q23.3. Four other
correlated SNPs in the BUD13/ZNF259 region reached
genome-wide signiﬁcance and were in moderate linkage dise-
quilibrium (LD) with rs964184 (range of r
2 ¼ 0.2–0.6):
rs180326 (r
2 ¼ 0.27), rs7350481 (r
2 ¼ 0.56), rs12292921
(r
2 ¼ 0.26) and rs12272004 (r
2 ¼ 0.20) (Fig. 2). We ﬁt
sequential general linear regression models to test whether
the association of each of these four SNPs was independent
of that of rs964184 using a likelihood ratio test. Results
showed none of the SNPs to be independently associated
with circulating alpha-tocopherol after controlling for
rs964184 and the covariates used in the ATBC GWAS analy-
sis (likelihood ratio test P-values for the four SNPs are 0.13,
0.89, 0.11 and 0.18, respectively), suggesting that the ﬁve var-
iants represent an association signal derived from a common
source and rs964184 is the marker with the strongest associ-
ation with alpha-tocopherol concentrations. One of the statisti-
cally signiﬁcant (although, not independent) signals,
rs12272004 (P ¼ 5.1 × 10
28), was previously reported to be
associated with serum alpha-tocopherol (P ¼ 3.9 × 10
27)i n
a previous GWAS (13).
This chromosomal region contains several genes involved
in cholesterol and lipid metabolism including APOA4,
APOA5 and APOC3 (15–17). The rs12272004 SNP has
been reported to be correlated with the S19W APOA5 SNP
(13). The rs964184 variant allele, associated with increased
alpha-tocopherol, has also been associated with decreased cir-
culating HDL cholesterol and increased triglyceride concen-
trations (18–20). Although not reaching genome-wide
signiﬁcance, an association has been suggested between
rs12292921 and triglyceride concentrations (P ¼ 1.3 × 10
23)
(15). Of the ﬁve variants, rs12272004 and rs12292921 were
not highly correlated with our primary SNP related to alpha-
tocopherol concentrations (rs964184; LD r
2’s ¼ 0.20 and
0.26, respectively), but were highly correlated with each
other (rs12292921 and rs12272004; LD r
2 ¼ 0.88). Many of
the other SNPs (n ¼ 41) previously identiﬁed in meta-analyses
as being related to circulating lipids (21,22) were not,
however, signiﬁcantly associated with alpha-tocopherol
levels in our study, although most (75%) were consistent
with respect to effect directionality (Supplementary Material,
Table S2).
We also found a novel association between increased cir-
culating alpha-tocopherol and a variant in CYP4F2
(rs2108622; P ¼ 1.7 × 10
28) on chromosome 19pter-p13.1.
One other nearby SNP, rs2074901 approached genome-wide
signiﬁcance (P ¼ 1.3 × 10
26;L Dr
2 ¼ 0.50, Fig. 3). After
conditioning on rs2108622, however, rs2074901 was no
longer signiﬁcantly associated with alpha-tocopherol (P ¼
0.31), indicating the association was not independent of
rs2108622. CYP4F2 contributes to vitamin E metabolism
by catalyzing tocopherol phytyl side-chain oxidation (23–
25). The rs2108622 variant has also been associated with
elevated hepatic vitamin K1 concentrations (26) and altered
fatty acid metabolism (23). Carriers of one or two copies
of the variant allele were recently shown to require higher
warfarin dosing for adequate coagulation compared with
those homozygous for the common allele in a GWAS
study of Japanese patients (27). According to results of
recent meta-analyses, rs2108622 is not associated with trigly-
cerides (P-values ranging from 0.39 to 0.97) (19,20), sup-
porting a non-lipid transport function for CYP4F2 in
vitamin E metabolism.
A signiﬁcant association between a common variant in
SCARB1 (rs11057830; P ¼ 2.0 × 10
28) and alpha-
tocopherol levels was also observed; no other SNPs
approached genome-wide signiﬁcance (Fig. 4). A candidate-
gene study showed two other SNPs in SCARB1 (i.e. in
exons 1 and 8) to be signiﬁcantly related to plasma concen-
trations of gamma-tocopherol (P ¼ 0.027) and alpha-
tocopherol (P ¼ 0.037) in men (28). The SCARB1 protein,
which is encoded in the region of chromosome 12q24.31,
has been implicated in the transfer of alpha-tocopherol
from HDL to tissues (29). Other SCARB1 SNPs (e.g.
rs9919713, three variants at exons 1 and 8 and intron 5,
and rs838880) have been associated with insulin-resistance,
increased HDL, lower LDL and/or higher body mass
index (21,30,31). Our ﬁnding is of interest in that promising
signals from SNP markers in this region also appear associ-
ated with risk for renal cell carcinoma (32), a cancer for
which body mass index (BMI) and obesity are established
risk factors. The LD, however, was low
(r
2 ¼ 0.01) between our SCARB1 signal and rs838880; the
other SCARB1 SNPs (including surrogates) were not avail-
able in our scan data.
The three SNP markers (rs964184, rs2108622, rs11057830)
together explain 1.7% of the variance in log-transformed
alpha-tocopherol concentration in the ATBC samples after
adjusting for age, BMI, cholesterol and cancer status.
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A GWAS analysis of gamma-tocopherol levels was conducted
in992participantsinthePLCOstudyandidentiﬁedassociations
between log-transformed circulating levels and variants in the
following four regions (Supplementary Material, Table S1):
rs847915 [TAS2R2 (taste receptor, type 2, member 2), P ¼
2.7 × 10
27] on chromosome 7; rs6865300 (NA, P ¼ 4.7 ×
10
27) and rs442392 (NA, P ¼ 6.0 × 10
27;L Dr
2 ¼ 0.54) on
chromosome 5; and rs3815951 in ARHGAP17 (Rho GTPase
activating protein 17), P ¼ 9.1 × 10
27 on chromosome 16.
The loci associated with the alpha-tocopherol levels were not
related to gamma-tocopherol (rs964184, P ¼ 0.81; rs2108622,
P ¼ 0.09; rs11057830, P ¼ 0.58). ARHGAP17 plays a central
role in epithelial apical polarity through regulation of CDC42,
a small G protein. For the two SNPs on chromosome 5, results
of sequential general linear models showed rs6865300 to be
independently associated with gamma-tocopherol levels.
DISCUSSION
Three independent genetic loci were identiﬁed in association
with circulating alpha-tocopherol concentrations. Further-
more, the SNP markers localize to candidate genes that have
a strong biological basis in the transport and metabolism of
vitamin E, including association with circulating lipoproteins.
The magnitudes of the estimated betas reported in this discov-
ery study were small, ranging from 0.03 to 0.04, and in com-
bination explained only 1.7% of the variance in concentrations
among individuals. Additional studies are needed to reﬁne the
estimates of the associations and to accurately conﬁrm the
effect sizes.
To our knowledge, only one previous GWAS examined the
circulating alpha-tocopherol phenotype (13). Consistent with
that investigation, we observed a marker with genome-wide
signiﬁcance, rs12272004, but this common variant was in
moderate LD and not independent of our most signiﬁcant
SNP, rs964184.
Because our analysis for discovering common variants
associated with gamma-tocopherol levels was not well-
powered and could represent a false positive ﬁnding,
additional studies are needed to re-examine those associations.
It is, however, notable that our ﬁndings for gamma-tocopherol,
a compound differing from alpha-tocopherol only by the
absence of one methyl group at the C-5 position of the
chroman ring identiﬁed different candidate regions. This
underscores the complexity of the pathways that contribute
to the metabolism of circulating vitamin E congeners.
Among the inherent strengths of our study is the large
sample size and conﬁrmation of ﬁndings in independent popu-
lations. Because baseline information on factors known
Figure 1. Manhattan plot of the P-values in the serum alpha-tocopherol
GWAS (ATBC). The x-axis represents chromosomal locations and the
y-axis shows P-values on a logarithmic scale.
Table 1. Baseline characteristics of GWAS study cohorts
Characteristic ATBC (n ¼ 4014) PLCO (n ¼ 992) NHS (n ¼ 2775)
Cases/controls, n 2402/1612 475/517 1416/1359
Age at randomization (years)
Mean+SD 58.1+5.0 64.6+4.9 59.2+6.3
Median (range) 58 (49–70) 65 (55–74) 60 (43–70)
BMI (kg/m
2)
Mean+SD 26.2+3.7 27.4+3.7 25.8+4.9
Median (range) 25.9 (16.1–49.4) 27.0 (19.7–43.7) 24.7 (15.6–52.2)
Serum total cholesterol (mg/dL)
Mean+SD 241.4+44.8 236.2+74.6 224.7+32.9
Median (range) 239.0 (110.2–460.2) 222.0 (77.0–579.3) 224.0 (116.0–414.6)
Serum HDL cholesterol (mg/dL)
Mean+SD 46.0+11.6 — —
Median (range) 11.1 (11.3–139.2) — —
Alpha-tocopherol (mg/L)
Mean+SD 11.9+3.4 19.1+9.7 13.3+5.8
Median (range) 11.5 (1.9–52.9) 16.8 (5.8–102.5) 12.0 (0.5–61.6)
Gamma-tocopherol (mg/L)
Mean+SD — 3.3+1.9 2.1+1.2
Median (range) — 2.9 (2.2–13.2) 1.9 (0.2–11.6)
SD, standard deviation.
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existed in the parent study, we were able to elucidate the inde-
pendent effects of SNPs by multivariable adjustment. Our
study is limited in that triglycerides were not measured and
therefore we were unable to directly account for them in the
GWAS; however, we did adjust for total cholesterol and
non-HDL levels which did not alter the study ﬁndings.
Because triglyceride data were unavailable in the present
study, we are unable to rule out the possibility that the
observed signal may be secondary to, or inﬂuenced by, the
associations previously reported for triglycerides (21). It is
possible that the association we observed for rs964184 is
reﬂecting the strong association previously reported for trigly-
cerides (P ¼ 7 × 10
2240). For rs11057830 (SCARB1), the
relation with triglycerides is not well-established (P-values
¼ 0.001, 0.30 and 0.80) according to previous meta-analyses
Figure 2. Association and recombination hotspot for rs964184 SNP on chromosome 11. LR ¼ the recombination rate on a logarithmic scale with 12 being
‘notable’ for a hotspot.
Table 2. Genetic variants associated with circulating alpha-tocopherol concentrations in the GWAS
SNP Chr Location Gene MAF (allele) Study P-value Beta SE Mean
alpha-tocopherol
(mg/L) by genotype
(number of minor
alleles)
012
rs964184 11 116154127 BUD13/ZNF259/APOA5 0.15 (G)
GWAS ATBC 2.7 × 10
210 0.04 0.01 11.6 12.5 13.6
Replication PLCO 5.9 × 10
21 20.01 0.02 19.3 18.6 19.2
Total NHS 7.2 × 10
24 0.05 0.01 — — —
NHS-CGEMS 5.6 × 10
22 0.03 0.02 13.2 13.9 13.3
NHS-CHD 1.9 × 10
22 0.08 0.03 13.0 13.8 16.3
NHS-T2D 2.5 × 10
22 0.09 0.04 13.1 14.9 17.4
Combined meta-analysis 7.8 × 10
212 0.04 0.01 — — —
rs2108622 19 15851431 CYP4F2 0.21 (T)
GWAS ATBC 1.7 × 10
28 0.04 0.01 11.8 12.1 12.7
Replication PLCO 1.8 × 10
22 0.05 0.02 18.6 19.6 20.3
Total NHS 2.7 × 10
22 0.02 0.01 — — —
NHS-CGEMS 1.7 × 10
22 0.03 0.01 13.2 13.5 14.3
NHS-CHD 1.0 × 10
21 0.04 0.03 12.7 13.6 14.7
NHS-T2D 1.5 × 10
21 20.05 0.03 13.9 13.5 12.7
Combined meta-analysis 1.4 × 10
210 0.03 0.01 — — —
rs11057830 12 123873006 SCARB1 0.15 (A)
GWAS ATBC 2.0 × 10
28 0.04 0.01 11.8 12.2 12.7
Replication PLCO 7.3 × 10
21 20.01 0.03 19.1 18.5 18.0
Total NHS 3.9 × 10
22 0.03 0.01 — — —
NHS-CGEMS 3.3 × 10
21 0.02 0.02 13.4 13.5 13.9
NHS-CHD 4.4 × 10
22 0.06 0.03 12.9 14.3 13.1
NHS-T2D 3.8 × 10
21 0.03 0.04 13.6 13.5 15.1
Combined meta-analysis 8.2 × 10
29 0.03 0.01 — — —
MAF, minor allele frequency; SE, standard error. The regression beta and standard error were based on logarithmic scale.
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(CYP4F2) is novel and does not reﬂect an inﬂuence of trigly-
cerides or transport in circulation. Previous meta-analyses
have not reported a signiﬁcant association for this CYP4F2
SNP and triglyceride levels (P-values range from 0.39 to
0.93) (19–21). Another potential limitation is that all partici-
pants in our primary scan were male smokers; therefore, poss-
ible modifying effects of smoking status on the observed
associations cannot be excluded. Previous studies have
demonstrated that cigarette smoking increases the concen-
tration of triglycerides and decreases HDL cholesterol (33–
35). In addition, smoking-associated free radicals deplete
vitamin E and other anti-oxidants (36). Our main ﬁndings
for the three loci did, however, replicate in an independent
population of women comprised of primarily never smokers,
suggesting that heterogeneity in the circulating vitamin
E-genetic associations based on smoking status is unlikely.
In conclusion, we found strong evidence that common
genetic variants on 11q23.3, within or near BUD13, ZNF259
and the APOA1/C3/A4/A5 gene cluster are associated with cir-
culating alpha-tocopherol levels. Our study identiﬁed two
additional SNP markers, one that maps to 19pter-p13.11,
which includes the biologically plausible candidate gene
CYP4F2 and another on 12q24.31, which harbors SCARB1.
Further work is required to ﬁne map the regions discovered
in our GWAS in order to nominate the optimal variants for
functional studies designed to understand the biological basis
of the reported observations. Our ﬁndings have identiﬁed
regions of the genome that inﬂuence vitamin E biochemical
status and provide a framework for investigation of this
membrane-integrated micronutrient that is important in
complex chronic diseases, such as cardiovascular disease, dia-
betes, and cancer.
MATERIALS AND METHODS
We conducted a GWAS of serum alpha-tocopherol concen-
trations within the Alpha-Tocopherol, Beta-Carotene Cancer
Prevention (ATBC) Study cohort and replicated the ﬁndings
in a combined meta-analysis with the Prostate, Lung, Colorec-
tal and Ovarian Cancer Screening Trial (PLCO) Study and the
Nurses’ Health Study (NHS) (Table 1). Similarly, a separate
GWAS was performed for gamma-tocopherol concentrations
using available data from the PLCO Study.
Figure 4. Association and recombination hotspot for rs11057830 SNP on chromosome 12. LR ¼ the recombination rate on a logarithmic scale with 12 being
‘notable’ for a hotspot.
Figure 3. Association and recombination hotspot for rs2108622 SNP on chromosome 19. LR ¼ the recombination rate on a logarithmic scale with 12 being
‘notable’ for a hotspot.
3880 Human Molecular Genetics, 2011, Vol. 20, No. 19Brieﬂy, the ATBC Study was a randomized, double-blind,
placebo-controlled intervention trial conducted to determine
whether supplementation with alpha-tocopherol, beta-
carotene or both could prevent cancer (37). The participants
were all male smokers at study entry, aged 50–69 years,
and residents of southwestern Finland. Men were not eli-
gible for study inclusion if they reported a history of
cancer, had severe diseases limiting long-term participation
or took supplements of vitamins E (.20 mg/day) or A
(.20 000 IU/day) or beta-carotene (.6 mg/day). Fasting
blood samples were collected at baseline and stored at
2708C until analyzed. Serum alpha-tocopherol levels were
measured by high-performance liquid chromatography (38),
with a coefﬁcient of variation (CV) of 2.2%. Gamma-
tocopherol was not measured at study baseline. Serum
cholesterol levels were measured with an enzymatic assay
by the CHOD-PAP method (Boehringer Mannhein) (39).
GWAS data from the Illumina 550K platform were avail-
able for 4014 men that were also previously analyzed
with respect to circulating vitamin D levels (12).
The PLCO Study was a multi-center trial conducted in the
US to evaluate the effectiveness of cancer screening and
examine early markers of cancer (40). PLCO male participants
of Caucasian descent, aged 55–74 years, were included in the
present GWAS (n ¼ 992). Plasma concentrations of alpha-
and gamma-tocopherol were measured by CLIA. The CVs
for alpha- and gamma-tocopherol concentrations were 5.8
and 8.9%, respectively. Cholesterol was measured enzymati-
cally by a standard procedure at 378C on a Hitachi 912 auto-
analyzer. GWAS genotyping used both the Illumina 317K and
240K platforms, and as a result, SNP coverage (relative to the
Illumina 550K used for ATBC) for two of the loci associated
with circulating alpha-tocopherol, was incomplete. Genotype
imputation was therefore performed for rs964184 and
rs11057830 using IMPUTE2 to identify SNPs with the 1000
genomes project June 2010 release and HapMap 3 release 2
as the reference set. The imputed SNPs had a high imputation
quality score.
Data from the NHS, a cohort of US women, was also used
to replicate the most signiﬁcant ﬁndings (approximately 100
SNPs with P , 1 × 10
25 or higher) obtained in the original
GWAS. For the NHS samples, plasma tocopherol levels
were measured using reversed-phase, high-performance
liquid chromatography. The CVs for each batch were ≤13%
with the exception of one batch which had a CV of 22%.
Total cholesterol was assayed from plasma using the enzy-
matic methods described by Allain et al.( 41). The Affymetrix
6.0 platform was used for nested case–control studies of cor-
onary heart disease (CHD; n ¼ 425) and type 2 diabetes (T2D;
n ¼ 394), and Illumina 550K for breast cancer [Cancer
Genetic Markers of Susceptibility (CGEMS); n ¼ 1929].
Each study sample used the MACH to impute up to approxi-
mately 2.5 million autosomal SNPs with NCBI build 36 of
Phase II HapMap CEU data (release 22) as the reference
panel. All of the imputed SNPs had a high imputation
quality score.
Prior to analysis, tocopherol levels were log-transformed to
normalize the distributions. A linear model adjusted for age,
BMI and cancer status was used to relate the log-transformed
outcomes to a SNP by assuming an additive mode of
inheritance. Furthermore, because it is well established that
vitamin E levels are affected by circulating lipids, we further
adjusted the analyses for total cholesterol. Because HDL
cholesterol was available in the ATBC Study, we performed
a sensitivity GWAS analysis that adjusted for ‘non-HDL’
cholesterol levels (total minus HDL, or essentially LDL +
VLDL, which we would expect to more closely reﬂect trigly-
cerides) and yielded SNP ﬁndings identical to those adjusted
for total cholesterol. Additional models that included both
total cholesterol and HDL also provided similar results. The
likelihood ratio test was used to detect the association
between the tocopherol levels and the SNPs, adjusting for
the above covariates. To identify the independent effect of
other SNPs in the region of the most signiﬁcant SNP, the like-
lihood ratio test was again used in the initial GWAS sample
with the most signiﬁcant SNP and those covariates involved
in the basic model. We used a ﬁxed effects meta-analysis on
the GWAS and replication studies. The meta-analysis was
conducted by combining the study-speciﬁc beta-estimates
weighted by the inverse of the corresponding variances. We
performed a sensitivity analysis on the alpha-tocopherol
GWAS, excluding subjects who reported any use of vitamin
E supplements (including those from multivitamins); the
identiﬁed SNPs remained signiﬁcant and accentuated among
non-users. Additionally adjusting the GWAS for HDL levels
did not change study ﬁndings. Study protocols for ATBC,
PLCO and NHS were approved by their respective insti-
tutional review boards and eligible participants provided
written consent.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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